Androgen Receptor (D6F11) XP ® Rabbit mAb (PE Conjugate) 8428S from Cell Signaling Technology | Biocompare.com

Supplier Images

Androgen Receptor (D6F11) XP ® Rabbit mAb (PE Conjugate)

Androgen Receptor (D6F11) XP ® Rabbit mAb (PE Conjugate)

Be the first to write a review!

Citations:

$450.00 Inquire

from
Cell Signaling Technology for
Androgen Receptor (D6F11) XP ® Rabbit mAb (PE Conjugate)

The Androgen Receptor (D6F11) XP ® Rabbit mAb (PE Conjugate) Antibody from Cell Signaling Technology is a Rabbit Monoclonal antibody to Androgen Receptor, and AR. This antibody recognizes Homo Sapiens, and Human antigen. The Androgen Receptor (D6F11) XP ® Rabbit mAb (PE Conjugate) Antibody has been shown to work in the following applications: Flow Cytometry.

Description

Androgen Receptor (D6F11) XP® Rabbit mAb (PE Conjugate) detects endogenous levels of total androgen receptor protein

Product Specs
ItemAndrogen Receptor (D6F11) XP ® Rabbit mAb (PE Conjugate)
CompanyCell Signaling Technology
Price $450.00 Inquire
Catalog Number8428S
Quantity100 µl
ApplicationsFC-FP
ReactivityH
TargetAndrogen Receptor
HostRabbit
NCBI Gene AliasesAIS, AR8, DHTR, HUMARA, HYSP1, KD, NR3C4, SBMA, SMAX1, TFM
Conjugate/TagPE
ClonalityMonoclonal
NCBI Full Gene Nameandrogen receptor
Research AreaNuclear Receptor Signaling
IsotypeIgG
CloneD6F11
Molecular Weight110

Add to Compare List

Cell Signaling Technology

Cell Signaling Technology

3 Trask Lane

Danvers, Massachusetts 01923

United States

Phone: 877-616-CELL
Phone: 978-867-2388
Fax: 866-432-6112
Fax: 978-867-2488

Company Profile

Website: http://www.cellsignal.com/

Website: Technical Support

(1) Targeting the Lnc-OPHN1-5/androgen receptor/hnRNPA1 complex increases Enzalutamide sensitivity to better suppress prostate cancer progressionCell death & diseaseSeptember 20, 2021Zhang M, Sun Y, Huang CP, Luo J, Zhang L, Meng J, Liang C, Chang C.paraffin. These samples were cut into 5 µm thick slices and dehydrated with xylene. We stained the AR (#8428, Cell Signaling Technology) and hnRNPA1 (Abcam, Cambridge, UK) antibodies at 4 °C incubator overnight

(2) Simultaneous use of erythropoietin and LFM-A13 as a new therapeutic approach for colorectal cancerBritish journal of pharmacologyMarch 1, 2018Tankiewicz-Kwedlo A, Hermanowicz JM, Domaniewski T, Pawlak K, Rusak M, Pryczynicz A, Surazynski A, Kaminski T, Kazberuk A, Pawlak D.

Be the First to Write a Review!